ZDHHC2 and prostate cancer: This study uncovers a previously unrecognized mechanism by which palmitoylation regulates ferroptosis through modulating ACSL4 stability, and highlights the ZDHHC2‐USP19‐ACSL4 axis as a druggable target for overcoming resistance in advanced prostate cancer.